Adagene Secures $25 Million Investment from Sanofi to Advance Cancer Therapies

Adagene ( (ADAG) ) has shared an update.

Adagene Inc. announced a strategic investment of up to $25 million from Sanofi, with the first closing of $17 million expected on July 2, 2025. The investment will support the development of Adagene’s anti-CTLA-4 SAFEbody, muzastotug, in a phase 2 trial for colorectal cancer. Sanofi also exercised its option for a third SAFEbody discovery program, highlighting the potential of Adagene’s platform. The collaboration is expected to extend Adagene’s cash runway into 2027, with a Sanofi representative joining Adagene’s Scientific Advisory Board.

The most recent analyst rating on (ADAG) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Adagene stock, see the ADAG Stock Forecast page.

Spark’s Take on ADAG Stock

According to Spark, TipRanks’ AI Analyst, ADAG is a Neutral.

Adagene’s overall stock score is significantly impacted by its poor financial performance, which remains the most critical factor. While technical analysis suggests some positive momentum, the lack of profitability and negative valuation metrics weigh heavily on the overall score. Investors should be cautious due to these financial challenges.

To see Spark’s full report on ADAG stock, click here.

More about Adagene

Adagene Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. Utilizing its proprietary Dynamic Precision Library platform, the company designs antibodies that address unmet patient needs globally. Adagene’s SAFEbody technology aims to improve safety and tolerability of antibody therapeutics by using precision masking technology, which allows for tumor-specific targeting while minimizing toxicity in healthy tissues.

Average Trading Volume: 34,456

Technical Sentiment Signal: Sell

Current Market Cap: $90.45M

Find detailed analytics on ADAG stock on TipRanks’ Stock Analysis page.